Stephen W. Webster - 02 Aug 2022 Form 4 Insider Report for Nabriva Therapeutics plc

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 02 Aug 2022
Net transaction value: -$1,487
SEC form: 4
Accepted by SEC: 04 Aug 2022, 18:20:55 UTC
Prior SEC filing: 24 Jun 2022
Next SEC filing: 19 Dec 2022
Source filing: View source filing
Reporting owner signature: /s/ J. Christopher Naftzger, by power of attorney

Key filing fact

Stephen W. Webster filed Form 4 for Nabriva Therapeutics plc on 04 Aug 2022.

Key facts

This page summarizes Stephen W. Webster's Form 4 filing for Nabriva Therapeutics plc.
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 04 Aug 2022, 18:20.

Change

Previous filing in this sequence was filed on 24 Jun 2022.
Current net transaction value: -$1,487.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NBRV transaction

Ordinary Shares

Sale

Transaction value: $1,487
Shares: -7,826
Change %: -41%
Price: $0.1900^*
Shares after: 11,447
Date: 02 Aug 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.1900 to $0.1911, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.